Role of Biomarkers in Cancer Diagnosis and Therapeutics offers a thorough exploration of the critical roles biomarkers play in cancer detection, diagnosis, monitoring, and therapy. Sections focus on established and emerging biomarkers like PSA and CEA, detailing their biochemical characteristics and clinical relevance, and examining metabolic pathways utilized by cancer cells, highlighting key enzymes and their therapeutic potential. The final part pf the book discusses innovative strategies targeting cell cycle checkpoints and DNA repair mechanisms, including synthetic lethality through PARP inhibitors. This essential resource provides researchers and clinicians with insights into novel metabolic targets and cutting-edge treatment strategies.
By addressing current applications and future challenges, including the integration of AI and multi-omics approaches, the book equips readers with actionable knowledge to advance personalized cancer care and navigate the dynamic landscape of oncology.
1. Chapter 15. Introduction to metabolic targets and autophagy - p. 305 2. Chapter 16. Glucose metabolism – Hexokinase-2, Lactate dehydrogenase A, Pyruvate kinase M2 isoform, Pyruvate dehydrogenase, Glucose transporter, enolase 1, and Monocarboxylate transporter - p. 345 3. Chapter 17. Nucleic acid metabolism as therapeutic target in cancer: a comprehensive analysis of folate cycle, nucleotide synthesis, and clinical applications - p. 393 4. Chapter 18. Amino acid metabolism - p. 413 5. Chapter 19. Glucose and amino acid metabolism - Isocitrate Dehydrogenase-1 - p. 433 6. Chapter 20. Glucose, nucleic acid, fatty acid, and amino acid metabolism – glyceraldehyde-3-phosphate dehydrogenase - p. 449 7. III: Miscellaneous cancer therapeutic approaches - p. P479 8. Chapter 21. Targeting DNA repair pathways - p. 481 9. Chapter 22. Cell cycle inhibition – Cyclin-Dependent Kinases, and G1 checkpoint - p. 513 10. Chapter 23. Targeting topoisomerases in oncology - p. 525 11. Chapter 24. Polo-like kinase 4 inhibitors in cancer therapy - p. 543 12. Chapter 25. Synthetic lethality by poly (ADP-ribose) polymerase inhibitors - p. 569 13. Chapter 26. Innovative therapeutic approaches - p. 589 14. Index - p. 641
Role of Biomarkers in Cancer Diagnosis and Therapeutics offers a thorough exploration of the critical roles biomarkers play in cancer detection, diagnosis, monitoring, and therapy. Sections focus on established and emerging biomarkers like PSA and CEA, detailing their biochemical characteristics and clinical relevance, and examining metabolic pathways utilized by cancer cells, highlighting key enzymes and their therapeutic potential. The final part pf the book discusses innovative strategies targeting cell cycle checkpoints and DNA repair mechanisms, including synthetic lethality through PARP inhibitors. This essential resource provides researchers and clinicians with insights into novel metabolic targets and cutting-edge treatment strategies.
By addressing current applications and future challenges, including the integration of AI and multi-omics approaches, the book equips readers with actionable knowledge to advance personalized cancer care and navigate the dynamic landscape of oncology.
1. Chapter 15. Introduction to metabolic targets and autophagy - p. 305 2. Chapter 16. Glucose metabolism – Hexokinase-2, Lactate dehydrogenase A, Pyruvate kinase M2 isoform, Pyruvate dehydrogenase, Glucose transporter, enolase 1, and Monocarboxylate transporter - p. 345 3. Chapter 17. Nucleic acid metabolism as therapeutic target in cancer: a comprehensive analysis of folate cycle, nucleotide synthesis, and clinical applications - p. 393 4. Chapter 18. Amino acid metabolism - p. 413 5. Chapter 19. Glucose and amino acid metabolism - Isocitrate Dehydrogenase-1 - p. 433 6. Chapter 20. Glucose, nucleic acid, fatty acid, and amino acid metabolism – glyceraldehyde-3-phosphate dehydrogenase - p. 449 7. III: Miscellaneous cancer therapeutic approaches - p. P479 8. Chapter 21. Targeting DNA repair pathways - p. 481 9. Chapter 22. Cell cycle inhibition – Cyclin-Dependent Kinases, and G1 checkpoint - p. 513 10. Chapter 23. Targeting topoisomerases in oncology - p. 525 11. Chapter 24. Polo-like kinase 4 inhibitors in cancer therapy - p. 543 12. Chapter 25. Synthetic lethality by poly (ADP-ribose) polymerase inhibitors - p. 569 13. Chapter 26. Innovative therapeutic approaches - p. 589 14. Index - p. 641
